文献速递肝病消化道肿瘤与早癌

HBV特异性TCR-T疗法SCG101治疗HBV相关肝细胞癌的临床结果

Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial.
PubMed 文献 · Gut · 2025-12-05

SCG101是一种靶向HBV的自体T细胞疗法,在研究者发起的试验中治疗6例晚期HBV相关肝细胞癌患者。所有患者出现短暂ALT升高和T细胞扩增,血清HBsAg两周内下降1.96 log10,3例肿瘤缩小,1例靶病灶完全缓解且无进展27个月。安全性事件可管理。

要点

  • SCG101在晚期HBV-HCC中显示抗病毒和抗肿瘤活性
  • 所有患者出现短暂ALT升高和T细胞扩增,细胞因子释放综合征可达3级但可管理
  • 3/6患者肿瘤缩小,1例靶病灶完全缓解并无进展27个月

核心结论

  • SCG101单药治疗HBV-HCC显示出显著的抗病毒和抗肿瘤活性,安全性可通过支持治疗管理。

研究设计与样本

  • 研究者发起的介入性试验,纳入6例HLA-A*02:01阳性、血清HBsAg阳性且HBeAg阴性的晚期HBV-HCC患者,既往接受过1至3线系统治疗失败。
  • 患者在淋巴清除后3天接受SCG101输注,剂量为5×10^7或1×10^8 TCR-T+细胞/kg。

主要发现

  • 1周内所有患者出现显著但短暂的ALT升高,外周血T细胞扩增76±57倍。
  • 未观察到神经毒性,但出现最高达3级的细胞因子释放综合征,副作用非剂量限制性,可用皮质类固醇、抗IL-6和/或升压药治疗。
  • 血清HBsAg水平在2周内下降1.96(0.16-3.84)log10。
  • 根据mRECIST,6例中3例肿瘤缩小,靶病灶最佳变化百分比分别为-19.5%、-74.6%和-100%。
  • 1例靶病灶完全缓解,无进展生存27个月;另1例达到持久(>6个月)缓解;随访中位10.9个月期间,3例死亡,1例失访。

临床怎么用

  • SCG101在经多线治疗失败的晚期HBV-HCC患者中显示出潜在抗病毒和抗肿瘤效果,但需进一步研究验证。
  • 治疗相关ALT升高和细胞因子释放综合征需密切监测并用皮质类固醇、抗IL-6及升压药等支持治疗管理。

局限性

  • 样本量小(6例),为研究者发起的早期试验,结论需更大规模研究证实。
  • 随访时间中位10.9个月,部分患者失访,长期疗效和安全性数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: SCG101 is an autologous T-cell therapy specifically targeting hepatitis B virus (HBV) using a natural, high-affinity T-cell receptor that is stably expressed. OBJECTIVE: We evaluated the safety, pharmacokinetics, pharmacodynamics and efficacy of SCG101 in patients with HBV-related hepatocellular carcinoma (HCC) in an investigator-initiated trial. DESIGN: Six human leucocyte antigen (HLA)-A*02:01-positive, serum hepatitis B surface antigen (HBsAg)-positive and hepatitis B e antigen-negative patients with advanced HBV-HCC, who had failed one to three prior systemic therapies, received SCG101 at doses of 5×107 or 1×108 TCR-T+ cells/kg three days after lymphodepletion. RESULTS: Within 1 week, all patients experienced a significant but transient alanine aminotransferase elevation paralleled by a 76±57 fold expansion of T cells detected in peripheral blood. No neurotoxicity, but a cytokine release syndrome reaching up to grade 3 was observed. However, these side effects were not dose-limiting and could be managed with corticosteroids, anti-interleukin-6 and/or vasopressor therapy. Indicating on-target activity of SCG101, serum HBsAg levels dropped by 1.96 (0.16-3.84) log10 within 2 weeks. According to modified Response Evaluation Criteria in Solid Tumours, three of the six patients achieved tumour shrinkage with a best percentage change in target lesion size of -19.5%, -74.6% and -100%. One showed complete remission of the target lesion, remaining progression-free for 27 months and one other achieved a durable (>6 months) remission. During follow-up (median 10.9 months), three patients died, and one was lost to follow-up. CONCLUSION: As monotherapy for patients with HBV-HCC, SCG101 demonstrated pronounced antiviral and antitumour activities and a safety profile manageable with supportive care. SCG101's T-cell expansion, serum HBsAg drop and tumour response collectively underscore on-target activity. TRIAL REGISTRATION NUMBER: NCT05339321.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Wu X, Quan D, Li W, et al. Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial. Gut. 2025. PMID: 40803751. doi:10.1136/gutjnl-2025-335456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。